Bavarian Nordic gets FDA approval for chikungunya vaccine
Bavarian Nordic (OTCPK:BVNRY) has received FDA approval for its vaccine Vimkunya for the prevention of chikungunya. The virus-like particle, or VLP, vaccine is approved for people aged 12 and older.
Hosted on MSN14d
EMA recommends Bavarian Nordic’s chikungunya vaccine for adults and teenagers
Bavarian Nordic’s chikungunya vaccine Vimkunya is one step closer to being available in Europe after having secured an European Medicines Agency (EMA) recommendation for a marketing authorisation. If ...
Info Salus14d
Empresas.- La EMA recomienda la comercialización de 'Vimkunya', primera vacuna frente al Chikungunya para adolescentes
La Agencia Europea del Medicamento (EMA, por sus siglas en inglés) ha recomendado conceder la autorización de comercialización a la vacuna 'Vimkunya', destinada a proteger frente al virus de ...